PERRIGO Co plc
Close on Oct 19, 2026
- Market cap
- $2.25B
- P/E (TTM)
- –
- Dividend yield
- 7.21%
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 27, 2026 | Aug 5, 2026 | Before market open | $1.02B | – | – |
| Q1 FY2026 Ended Mar 28, 2026 | May 6, 2026 | Before market open | $969.00M | $-2.81 | $0.43 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $1.11B | $-10.20 | $0.77 |
| Q3 FY2025 Ended Sep 27, 2025 | Nov 5, 2025 | Before market open | $1.04B | $0.09 | $0.80 |
| Q2 FY2025 Ended Jun 28, 2025 | Aug 6, 2025 | Before market open | $1.06B | $0.00 | $0.57 |
| Q1 FY2025 Ended Mar 29, 2025 | May 7, 2025 | Before market open | $1.04B | $0.00 | $0.60 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | During market hours | $1.14B | $-0.30 | $0.93 |
| Q3 FY2024 Ended Sep 28, 2024 | Nov 6, 2024 | Before market open | $1.10B | $-0.13 | $0.81 |
| Q2 FY2024 Ended Jun 29, 2024 | Aug 2, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 30, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adj. EPS (Core)non-GAAP | Fiscal 2026 | $2.25 to $2.55 | Maintained |
| Adj. Gross Margin (Core)non-GAAP | Fiscal 2026 | 39% to 40% | Maintained |
| Adj. Operating Margin (Core)non-GAAP | Fiscal 2026 | 15% to 16% | Maintained |
| Adjusted effective tax ratenon-GAAP | Fiscal 2026 | 18% | Lowered |
| Net leveragenon-GAAP | Fiscal 2026 | 4 | Maintained |
| Adjusted weighted average shares outstandingnon-GAAP | Fiscal 2026 | 139.3 | Lowered |
| Net interest expensenon-GAAP | Fiscal 2026 | $156.00M | New |
| Organic Core Net Sales Growthnon-GAAP | Fiscal 2026 | -3.5% to 0.5% growth | Lowered |
| Net Sales Growth (Core)non-GAAP | Fiscal 2026 | -3% to 1% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Perrigo filed with the SEC
Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Announces Appointment of Two New Independent Directors to Board
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Albert A. Manzone Appointed Interim President and CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Completes Divestiture of Dermacosmetics Business
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
QUARTERS AND FISCAL YEARS TO DATE 2025 and 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Nicholas Gallagher, Associate Director, Global Investor Relations, (269) 686-3238, E-mail: [email protected]
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Announces Proposed Divestiture of Dermacosmetics Business for up to 327 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Perrigo Announces Global Operations and Supply Chain Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K/A
Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Completes Divestment of HRA Pharma Rare Diseases Business
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program
Results of operations · EX-99.1 to Form 8-K
Perrigo Announces Early Results of Cash Tender Offer for Notes
Other events · EX-99.1 to Form 8-K
Perrigo Announces Cash Tender Offer for Notes
Other events · EX-99.1 to Form 8-K
Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Announces Chief Executive Officer Retirement and Succession Plan
Executive or director change · Other events · EX-99.1 to Form 8-K
Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations
Results of operations · EX-99.1 to Form 8-K
PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS
Results of operations · EX-99.1 to Form 8-K
PERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCE
Results of operations · EX-99.1 to Form 8-K
PERRIGO ANNOUNCES PLANNED LEADERSHIP SUCCESSION
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PERRIGO COMPLETES THE ACQUISITION OF HRA PHARMA
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
PERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA
Regulation FD disclosure · EX-99.1 to Form 8-K
PERRIGO ANNOUNCES CLOSING OF $2.6 BILLION SENIOR SECURED CREDIT FACILITIES
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.1 to Form 8-K
PERRIGO ANNOUNCES LAUNCH OF PRIVATE NOTES OFFERING
Other events · EX-99.1 to Form 8-K
reconciliation of pro forma EBITDA and pro forma Adjusted EBITDA to pro forma net income (loss), which is the most directly comparable financial measure prepared in accordance with GAAP:
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Statutory auditor’s report on the consolidated
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K